FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT
2 other identifiers
interventional
7
1 country
1
Brief Summary
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2015
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 25, 2015
CompletedFirst Submitted
Initial submission to the registry
September 12, 2016
CompletedFirst Posted
Study publicly available on registry
September 16, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 29, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 29, 2025
CompletedDecember 17, 2025
December 1, 2025
9.4 years
September 12, 2016
December 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Changes in glucose uptake
Standardized uptake values (SUV) will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established.
From baseline up to 48 hours
Very early changes in tumor glucose uptake predictive for objective treatments response and survival assessed using RANO criteria
SUV will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established.
One PET/CT 48 hours after start of therapy
Study Arms (1)
Treatment (FDG PET/CT)
EXPERIMENTALPatients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
Interventions
Undergo FDG PET/CT
Undergo FDG PET/CT
Undergo FDG PET/CT
Eligibility Criteria
You may qualify if:
- Patients with histologically proven high grade glioma
- Intention to start therapy
You may not qualify if:
- Severe psychiatric illness
- Inability to give written consent
- Breast feeding / pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jonsson Comprehensive Cancer Centerlead
- National Cancer Institute (NCI)collaborator
- National Institutes of Health (NIH)collaborator
Study Sites (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Johannes Czernin, MD
UCLA / Jonsson Comprehensive Cancer Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 12, 2016
First Posted
September 16, 2016
Study Start
August 25, 2015
Primary Completion
January 29, 2025
Study Completion
January 29, 2025
Last Updated
December 17, 2025
Record last verified: 2025-12